FAIR ACT Fast-tracking Approval for Innovative Rare disease therapies...
To accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing a reciprocal approval mechanism with trusted international regulatory authorities.
HB7953, also known as the FAIR ACT, aims to speed up access to cutting-edge treatments and clinical trials for individuals suffering from life-threatening rare diseases. This bill proposes to create a system that allows for the approval of innovative therapies through a reciprocal agreement with trusted international regulatory bodies.
This legislation would primarily benefit patients with rare diseases, their families, and the broader medical community by facilitating quicker access to potentially life-saving treatments. It could also encourage pharmaceutical companies to invest more in research and development for rare diseases.
As of March 17, 2026, HB7953 was introduced in the House and referred to the House Committee on Energy and Commerce. The bill is currently in the early stages of the legislative process, awaiting further review and potential action from the committee.
